Børresen-Dale AL - Search Results

1

High levels of genomic aberrations in serous ovarian cancers are associated with better survival.

Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P; Australian Ovarian Cancer Study Group; Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL. Baumbusch LO, et al. PLoS One. 2013;8(1):e54356. doi: 10.1371/journal.pone.0054356. Epub 2013 Jan 23. PLoS One. 2013. PMID: 23372714 Free PMC article.

2

Microsatellite instability in cervical and endometrial carcinomas.

Helland A, Børresen-Dale AL, Peltomäki P, Hektoen M, Kristensen GB, Nesland JM, de la Chapelle A, Lothe RA. Helland A, et al. Int J Cancer. 1997 Mar 4;70(5):499-501. doi: 10.1002/(sici)1097-0215(19970304)70:5<499::aid-ijc1>3.0.co;2-t. Int J Cancer. 1997. PMID: 9052745 Free article.

3

TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.

Skomedal H, Kristensen GB, Abeler VM, Børresen-Dale AL, Tropé C, Holm R. Skomedal H, et al. J Pathol. 1997 Feb;181(2):158-65. doi: 10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8. J Pathol. 1997. PMID: 9120719

4

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale AL. Smith-Sørensen B, et al. Br J Cancer. 1998 Aug;78(3):375-81. doi: 10.1038/bjc.1998.502. Br J Cancer. 1998. PMID: 9703286 Free PMC article. Clinical Trial.

5

TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.

Skomedal H, Kristensen GB, Nesland JM, Børresen-Dale AL, Tropé C, Holm R. Skomedal H, et al. J Pathol. 1999 Apr;187(5):556-62. doi: 10.1002/(SICI)1096-9896(199904)187:5<556::AID-PATH294>3.0.CO;2-Y. J Pathol. 1999. PMID: 10398121

6

Allelic imbalance at chromosome region 11q23 in cervical carcinomas.

Skomedal H, Helland A, Kristensen GB, Holm R, Børresen-Dale AL. Skomedal H, et al. Eur J Cancer. 1999 Apr;35(4):659-63. doi: 10.1016/s0959-8049(98)00413-4. Eur J Cancer. 1999. PMID: 10492643

7

p53 polymorphism and cervical cancer.

Helland A, Børresen-Dale AL. Helland A, et al. Lancet. 1999 Oct 30;354(9189):1561-2. doi: 10.1016/S0140-6736(05)76596-X. Lancet. 1999. PMID: 10551531 No abstract available.

8

Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival.

Helland A, Kraggerud SM, Kristensen GB, Holm R, Abeler VM, Huebner K, Borresen-Dale AL, Lothe RA. Helland A, et al. Int J Cancer. 2000 Oct 15;88(2):217-22. doi: 10.1002/1097-0215(20001015)88:2<217::aid-ijc11>3.0.co;2-i. Int J Cancer. 2000. PMID: 11004671 Free article.

9

Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas.

Dai H, Holm R, Kristensen GB, Abeler VM, Børresen-Dale AL, Helland A. Dai H, et al. Anal Cell Pathol. 2001;23(2):45-9. doi: 10.1155/2001/521873. Anal Cell Pathol. 2001. PMID: 11904459 Free PMC article.

10

X chromosome inactivation in cervical cancer patients.

Kristiansen M, Helland A, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale AL, Ørstavik KH. Kristiansen M, et al. Cancer Genet Cytogenet. 2003 Oct 1;146(1):73-6. doi: 10.1016/s0165-4608(03)00152-3. Cancer Genet Cytogenet. 2003. PMID: 14499700

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

508 results

Search Page